Results 191 to 200 of about 47,940 (359)

Ubiquitin C‐Terminal Hydrolase L1 (UCHL1), Beyond Hydrolysis

open access: yesBioEssays, EarlyView.
UCHL1 is a neuron‐enriched component of the ubiquitin‐proteasome system. This review debates the biological relevance of its biochemical roles: limited DUB activity, potential ligase function, and mono‐ubiquitin stabilization. We emphasize the need to clarify the mechanisms and identify natural substrates for each function to understand their role in ...
Anwar Bdarneh   +2 more
wiley   +1 more source

Nanomaterials for enhanced X‐ray‐triggered cancer therapy: Progress and prospects

open access: yesBMEMat, EarlyView.
This review summarizes the latest progress in nanomaterials for X‐ray‐triggered cancer therapy, highlighting their various advantages such as targeted delivery, reduced side effects, and enhanced therapeutic efficacy. Abstract X‐rays, a form of ionizing radiation with high energy and significant penetration capability, are commonly used in clinical ...
Yuanchun Chen   +6 more
wiley   +1 more source

Mass spectrometry in ocular drug research

open access: yesMass Spectrometry Reviews, EarlyView., 2023
Abstract Mass spectrometry (MS) has been proven as an excellent tool in ocular drug research allowing analyzes from small samples and low concentrations. This review begins with a short introduction to eye physiology and ocular pharmacokinetics and the relevance of advancing ophthalmic treatments.
Eva M. del Amo   +6 more
wiley   +1 more source

Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies

open access: yesNeurobiology of Disease, 2005
Destruction of nigrostriatal dopaminergic (DA) pathway triggers various persistent responses, such as inflammation and increased synthesis of neural growth factors, both in striatum and in substantia nigra.
Lei Xu   +9 more
doaj  

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

open access: yesBMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen   +7 more
wiley   +1 more source

Pre‐folding purification procedures for inclusion body‐derived non‐tagged cationic recombinant proteins with multiple disulfide bonds for efficient refolding

open access: yesBiotechnology Progress, EarlyView.
Abstract The production of disulfide‐containing recombinant proteins often requires refolding of inclusion bodies before purification. A pre‐refolding purification step is crucial for effective refolding because impurities in the inclusion bodies interfere with refolding and subsequent purification.
Shuichiro Kimura   +4 more
wiley   +1 more source

Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma

open access: yesCancer Communications, EarlyView.
Abstract Background Intrahepatic cholangiocarcinoma (ICC) is a challenging cancer with an increasing incidence. The Phase III TOPAZ‐1/KEYNOTE‐966 study demonstrated chemo‐immunotherapy (CIT) as a significant advancement, potentially replacing traditional chemotherapy for advanced biliary tract cancer.
Jinghan Zhu   +12 more
wiley   +1 more source

Advances in Cytosolic Delivery of Proteins: Approaches, Challenges, and Emerging Technologies

open access: yesChemistry &Biodiversity, EarlyView.
Proteins regulate almost all biological processes, and overcoming the protein's natural membrane inpermeability will provide a unique opportunity for intracellular targeting of related therapeutic proteins. Chemical modification of proteins and different types of delivery vectors can mediate intracellular transport of proteins, providing new ideas for ...
Wenyan Zhang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy